# TRACER Phase-L3 Matched Effect Closure v0

## Result

Phase-L3 compared realized flat-terrain candidate exposures against matched
empirical-equivalent controls.

The empirical-equivalent control pool consists of:

- empirical baseline flat windows
- control-equivalent Flat Noop windows
- control-equivalent J19 flat exposure windows

No evaluated non-noop candidate produced group-mean effects outside the
95th-percentile absolute no-op placebo variability band.

## Candidate interpretation

### Flat Slow03

Actual intervention:

```text
vx_scale = 0.97
Observed tendency:

small progress-rate penalty
weak improvement in lateral stability metrics

Decision:

uncertain_within_placebo

The evidence does not justify a beneficial action label.

Flat Clear03

Actual intervention:

clearance_delta = +0.003

Observed tendency:

negligible progress-rate change
lateral metrics trend toward degradation

Decision:

uncertain_within_placebo

The evidence does not justify a detrimental action label because the observed
changes remain inside the placebo variability envelope.

Flat Slow03 + Clear03

Actual intervention:

vx_scale = 0.97
clearance_delta = +0.003

Observed tendency:

small progress penalty
weak lateral-stability improvement tendency

Decision:

uncertain_within_placebo

The evidence does not justify a beneficial action label.

Main conclusion

Phase-K rollout decisions must not be converted directly into action-quality
labels.

Phase-L3 further shows that the currently tested flat micro-actions are too
weak, relative to observed rollout variability, to provide reliable
beneficial/detrimental supervision.

Therefore:

beneficial labels: 0
detrimental labels: 0
uncertain interventions: 18 reconstructed windows

No learned selector should be trained from these effect labels yet.

Runtime decision
active runtime = empirical/default
candidate promotion = none
Next step

Phase-L4 should use a systematic experimental candidate design rather than
continued manual micro-action tuning.

The experiment should:

preserve an empirical/no-op control group,
use explicit candidate residual magnitudes,
randomize or interleave control and candidate trials,
use guarded active exposure only,
collect repeated paired evidence,
estimate action effects before assigning selector labels.

The initial L4 purpose is effect identifiability and dataset expansion, not
candidate deployment.
